200 related articles for article (PubMed ID: 23396091)
1. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.
Zeitlin L; Bohorov O; Bohorova N; Hiatt A; Kim DH; Pauly MH; Velasco J; Whaley KJ; Barnard DL; Bates JT; Crowe JE; Piedra PA; Gilbert BE
MAbs; 2013; 5(2):263-9. PubMed ID: 23396091
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in
Pisuttinusart N; Rattanapisit K; Srisaowakarn C; Thitithanyanont A; Strasser R; Shanmugaraj B; Phoolcharoen W
Hum Vaccin Immunother; 2024 Dec; 20(1):2327142. PubMed ID: 38508690
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117
[TBL] [Abstract][Full Text] [Related]
6. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
8. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
Claydon J; Sur A; Callejas A; Ladd M; Kwan E; Taylor R; Turvey SE; Solimano A; Lavoie PM; Marr N
PLoS One; 2017; 12(4):e0176152. PubMed ID: 28437470
[TBL] [Abstract][Full Text] [Related]
12. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
14. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus.
Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T
Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879
[TBL] [Abstract][Full Text] [Related]
15. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.
Hiatt A; Bohorova N; Bohorov O; Goodman C; Kim D; Pauly MH; Velasco J; Whaley KJ; Piedra PA; Gilbert BE; Zeitlin L
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):5992-7. PubMed ID: 24711420
[TBL] [Abstract][Full Text] [Related]
16. Binding and Neutralizing Capacity of Respiratory Syncytial Virus (RSV)-Specific Recombinant IgG Against RSV in Human Milk, Gastric and Intestinal Fluids from Infants.
Demers-Mathieu V; Lueangsakulthai J; Qu Y; Scottoline BP; Dallas DC
Nutrients; 2020 Jun; 12(7):. PubMed ID: 32605037
[TBL] [Abstract][Full Text] [Related]
17. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats.
Smith G; Raghunandan R; Wu Y; Liu Y; Massare M; Nathan M; Zhou B; Lu H; Boddapati S; Li J; Flyer D; Glenn G
PLoS One; 2012; 7(11):e50852. PubMed ID: 23226404
[TBL] [Abstract][Full Text] [Related]
19. In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.
Ramirez KA; Mond J; Papenburg J; Boivin G; Gilbert BE; Falsey AR; Bagga B; DeVincenzo JP
Virology; 2023 Sep; 586():115-121. PubMed ID: 37542818
[TBL] [Abstract][Full Text] [Related]
20. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
Wu H; Pfarr DS; Losonsky GA; Kiener PA
Curr Top Microbiol Immunol; 2008; 317():103-23. PubMed ID: 17990791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
